ADA and psoriasis: As reported previously for the VOYAGE 1 active-comparator study, 837 patients with longstanding moderate-to-severe psoriasis were randomized to placebo (n = 174), guselkumab (n = 329), or ADA (n = 334) and were treated through week 48 (Blauvelt et al, 2017, NCT02207231).